PD07-11 THERMAL ABLATION FOR ADRENAL METASTASES: A POOLED META-ANALYSIS AND SYSTEMATIC REVIEW OF 11 STUDIES WITH 339 PATIENTS

Abstract

You have accessJournal of UrologyAdrenal (PD07)1 Sep 2021PD07-11 THERMAL ABLATION FOR ADRENAL METASTASES: A POOLED META-ANALYSIS AND SYSTEMATIC REVIEW OF 11 STUDIES WITH 339 PATIENTS Run-Qi GUO, and Xiao-Guang LI Run-Qi GUORun-Qi GUO More articles by this author , and Xiao-Guang LIXiao-Guang LI More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000001975.11AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Thermal ablation (TA) has been reported to be safe and effective in the treatment of various malignancies. Although TA is available in the treatment of adrenal metastases (AM), the data are still limited. The aim of this study was to systematically evaluate the efficacy, outcomes and safety of TA for AM. METHODS: We did a systematic review and meta-analysis to aggregate the clinical outcomes of patients with AM treated with TA. We searched PubMed, EMBASE, and the Cochrane Library for studies published between January 2001 and January 2021, reporting the use of TA for AM. Proportionality with 95% confidence intervals (CIs) were performed using STATA version 14.0. RESULTS: Our search returned 301 studies, of which 48 were assessed for full-text eligibility. 11 studies, reporting on 339 patients with AM, were eligible for systematic review and included in the meta-analysis. The technical success rate 100% (99%-100%).The local tumor control rate (95% CI) at 1, 2, 3, and 5 years was 85% (81%-88%), 79% (73%-85%), 71% (61%-82%), and 63% (54%-72%). The overall survival at 1, 2, 3, and 5 years was 74% (67%-82%), 50% (38%-64%), 35% (29%-42%), and 27% (18%-36%). The major complication rate and the incidence of hypertensive crisis were 6.8% (3.2%-10.4%) and 30.2% (11.8%-48.6%). CONCLUSIONS: TA is an efficacious method of treating AM, with reliable tumor control rates and overall survival. Randomized controlled trials should further evaluate the safety and efficacy of TA in this setting. Source of Funding: This study is supported by Scientific Research Starting Foundation for PhD/MD under Grant BJ-2019-135 and Scientific Research Foundation for Central Health Care under Grant 2020YB10 © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e110-e112 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Run-Qi GUO More articles by this author Xiao-Guang LI More articles by this author Expand All Advertisement Loading ...